iBio Inc. (NYSEAMERICAN:IBIO) and aTyr Pharma Inc. (NASDAQ:LIFE) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio Inc.	N/A	18.43	17.51M	-1.22	0.00
aTyr Pharma Inc.	N/A	0.00	34.52M	-1.33	0.00

In table 1 we can see iBio Inc. and aTyr Pharma Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us iBio Inc. and aTyr Pharma Inc.’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
iBio Inc.	0.00%	-157.6%	-44.5%
aTyr Pharma Inc.	0.00%	-78.1%	-53.6%

Risk and Volatility

iBio Inc. has a beta of 1.06 and its 6.00% more volatile than S&P 500. aTyr Pharma Inc.’s 2.42 beta is the reason why it is 142.00% more volatile than S&P 500.

Institutional and Insider Ownership

The shares of both iBio Inc. and aTyr Pharma Inc. are owned by institutional investors at 8% and 52.6% respectively. 45.24% are iBio Inc.’s share owned by insiders. Comparatively, insiders own roughly 2.5% of aTyr Pharma Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
iBio Inc.	-14.88%	-2.16%	5.09%	18.19%	-57.16%	12.98%
aTyr Pharma Inc.	-7.27%	-11.18%	-26.45%	-38.19%	-84.92%	-10.23%

For the past year iBio Inc. had bullish trend while aTyr Pharma Inc. had bearish trend.

Summary

iBio Inc. beats aTyr Pharma Inc. on 5 of the 7 factors.

iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has license and collaboration agreements with Caliber Biotherapeutics LLC and Fiocruz; and collaboration agreements with the A & M University System, AzarGen Biotechnologies (Pty) Ltd, Fraunhofer Center for Molecular Biotechnology, and Theoremdx, Inc. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is based in New York, New York.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.